본문 바로가기

Modulation of Rat Hepatic CYP1A and 2C Activity by Honokiol and Magnolol: Differential Effects on Phenacetin and Diclofenac Pharmacokinetics In Vivo

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q2Scopus Q1
저널
MOLECULES23(6) · 2018
피인용
Web of Science 8Scopus 12
FWCI (Scopus)
0.7
JCR IF
JCR 2017 3.098
ISSN
1420-3049

저자

  1. Kim, Sang-Bum제1저자New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, South Korea
  2. Kim, Kyu-SangCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, South Korea
  3. Ryu, Heon-MinCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, South Korea
  4. Hong, Seong-HoBiomedicine Lab, CKD Research Institute, Gyeonggi, South Korea
  5. Kim, Bo-KyoungNew Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, South Korea
  6. Kim, Dae-DukCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, South Korea
  7. Park, Jin WooDepartment of Pharmacy, College of Pharmacy, Natural Medicine Research Institute, Mokpo National University, Jeonnam, South Korea
  8. 윤인수교신저자Department of Manufacturing Pharmacy, College of Pharmacy, Pusan National University, Busan, South Korea

초록

Honokiol (2-(4-hydroxy-3-prop-2-enyl-phenyl)-4-prop-2-enyl-phenol) and magnolol (4-Allyl-2-(5-allyl-2-hydroxy-phenyl) phenol) are the major active polyphenol constituents of Magnolia officinalis (Magnoliaceae) bark, which has been widely used in traditional Chinese medicine (Houpu Tang) for the treatment of various diseases, including anxiety, stress, gastrointestinal disorders, infection, and asthma. The aim of this study was to investigate the direct effects of honokiol and magnolol on hepatic CYP1A and 2C-mediated metabolism in vitro using rat liver microsomes and in vivo using the Sprague-Dawley rat model. Honokiol and magnolol inhibited in vitro CYP1A activity (probe substrate: phenacetin) more potently than CYP2C activity (probe substrate: diclofenac): The mean IC50 values of honokiol for the metabolism of phenacetin and diclofenac were 8.59 mu M and 44.7 mu M, while those of magnolol were 19.0 mu M and 47.3 mu M, respectively. Notably, the systemic exposure (AUC and C-max) of phenacetin, but not of diclofenac, was markedly enhanced by the concurrent administration of intravenous honokiol or magnolol. The differential effects of the two phytochemicals on phenacetin and diclofenac in vivo pharmacokinetics could at least be partly attributed to their lower IC50 values for the inhibition of phenacetin metabolism than for diclofenac metabolism. In addition, the systemic exposure, CL, and V-ss of honokiol and magnolol tended to be similar between the rat groups receiving phenacetin and diclofenac. These findings improve our understanding of CYP-mediated drug interactions with M. officinalis and its active constituents.

키워드

honokiolmagnololMagnolia officinalisCYP1ACYP2CratpharmacokineticsHUMAN LIVER-MICROSOMESBARK EXTRACTCYTOCHROME-P450 ENZYMESCHEWING GUMINHIBITIONOFFICINALISPROTECTSBIOAVAILABILITYPRETREATMENTTOLBUTAMIDE

식별자

Scopus EID
2-s2.0-85048945399
WoS UID
000435875400231